SecBot SecBot
PRESS-RELEASE ·Filed Oct 26, 2026

XLO

Xilio Therapeutics, Inc.
NEUTRAL
Impact 4/10
Processed1h 38m ago Wirepress-3387997
Press release · FDA

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3387997
12 reports for XLO
Performance horizon
100% Hit rate @ T+5 5 of 5 directional calls Went positive at some point 5 of 5 best @ T+60▲ +19.92%May 12, 2026
Filters
Rows
Reports for XLO — sortable, filterable
TypeNow
Oct 26, 2026
today
Press Release
NEUTRAL ★ 4/10
—awaiting T+5——
Aug 12, 2026
10w ago
8-K
BULLISH ★ 7/10
$9.05 $9.41▲ +3.98%▲ +4.42%$7.57 (−16.35%)
Aug 12, 2026
10w ago
Press Release
BULLISH ★ 7/10
$9.05 $9.41▲ +3.98%▲ +4.42%$7.57 (−16.35%)
Jun 1, 2026
21w ago
EFFECT
BEARISH ★ 5/10
$8.25 $7.70▲ +6.67%▲ +3.92%$7.57 (+8.24%)
May 27, 2026
21w ago
S-3/A
NEUTRAL ★ 4/10
$8.52 $8.15▼ −4.40%▼ −4.35%$7.57 (−11.15%)
May 12, 2026
23w ago
8-K
NEUTRAL ★ 4/10
$7.73 $8.15▲ +5.43%▲ +5.36%$7.57 (−2.07%)
May 12, 2026
23w ago
Press Release
BULLISH ★ 7/10
$7.73 $8.15▲ +5.43%▲ +5.36%$7.57 (−2.07%)
Apr 17, 2026
27w ago
Press Release
MIXED ★ 5/10
$8.45 $8.18▼ −3.20%▼ −4.11%$7.57 (−10.41%)
Apr 16, 2026
27w ago
3
NEUTRAL ★ 2/10
$8.57 $8.31▼ −3.03%▼ −3.59%$7.57 (−11.67%)
Apr 16, 2026
27w ago
8-K
NEUTRAL ★ 3/10
$8.35 $8.47▲ +1.44%▲ +0.45%$7.57 (−9.34%)
Showing 10 of 12

US Market Status

Market Closed — Opens in 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh XLO Intelligence

Analysis is for subscribers only.

Xilio Therapeutics announced dosing of the first patient in a Phase 1/2 trial of XTX501, a PD-1/masked IL-2 bispecific, for metastatic NSCLC. The company plans to present a trial-in-progress poster at SITC in November 2026 and expects initial Phase 1 data in Q4 2027.

Subscribe for Full Access